fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves manufacturing process change resulting in reduced median turnaround time for Yescarta CAR T-cell therapy – Kite/Gilead Sciences

Written by | 4 Feb 2024

Kite, a Gilead Company announced that the FDA has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta (axicabtagene ciloleucel). With this approval, Kite’s… read more.

New immunotherapy holds promise for ovarian cancer

Written by | 8 Feb 2023

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system’s T cells are programmed to attack tumour cells, is effective in mice with ovarian… read more.

Immunity boosting treatment enhances CAR-T cell therapy for blood cancers

Written by | 15 Jun 2022

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are… read more.

Researchers shorten manufacturing time for CAR T cell therapy

Written by | 1 Apr 2022

A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.